BIOMUNEX is a biopharmaceutical company based in Paris (FR), with an office in Cambridge, Massachusetts, USA, with a seasoned and international leadership team and board. BIOMUNEX is discovering and developing differentiated immunotherapeutic approaches based on data driven biology, to address the unmet medical needs in oncology.

BIOMUNEX focuses on inventing disruptive biological approaches and bringing breakthrough therapies to patients based on the discovery and development of its next generation proprietary BiXAb® bi- and multispecific antibodies.

  • Our game changing proprietary BiXAb® technology enables BIOMUNEX to discover and develop immunotherapies for multiple cancer types. Antibodies generated through the BiXAb® platform process offer key properties of an ideal bispecific platform: rapid design, less than 6 weeks from in silico design to characterization of an original bispecific antibody, and modularity; excellent drug like properties; high production yields and cost-effective manufacturability; multi-specific capability and versatility.

  • Our most advanced BiXAb® candidates, developed for immuno-oncology applications, have demonstrated impressive in vitro and in vivo efficacy in solid tumors and hematological malignancies. BIOMUNEX has also initiated several collaborations with key renowned academic institutions such as the Institut Curie in Paris for the development of the next generation of bispecific antibodies using the recently discovered sub-population of T-cells, the MAITs (Mucosal-Associated Invariant T cells).

  • The BiXAb® technology and pipeline have been validated by licensing deals signed with industrial partners for development of bi- and multi-specific antibodies, in line with the company’s strategy of collaboration agreements with major pharma partners:

    • In 2019 – Out-licensing agreement with SANOFI focused on generation and optimization of bi- and multi-specific antibody therapeutics.

    • In 2021 – Out-licensing and co-development agreement with ONWARD Therapeutics for one of the proprietary bi-specific antibody programs of BIOMUNEX.

  • The BiXAb® technology of BIOMUNEX Pharmaceuticals has also been validated by the start of a Phase 1 clinical trial for its first-in-class bi-specific antibody for the treatment of cancer, announced in January 2024:

    • This first-in-man trial conducted by ONWARD Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bi-specific antibody generated from BIOMUNEX’ proprietary BiXAb® platform.

    • The Phase 1 study is evaluating the safety, tolerability, pharmacokinetics, immunogenicity and preliminary anti-tumoral activity of a “first-in-class” bispecific antibody targeting two immune checkpoints (OT-A201), given as monotherapy or in combination in patients with either solid tumors or hematological malignancies.

    • The enrollment of the first patient in this clinical trial demonstrates the potential of the BiXAb® platform to generate clinical candidates. It also triggered the first clinical milestone payment by ONWARD Therapeutics to BIOMUNEX.